Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 100, Issue 3

Oncogenicitiy Comparison of Human Papillomavirus Type 52 E6 Variants No Access

Abstract

Human papillomavirus (HPV) infection contributes to virtually all cases of cervical cancer, the fourth most common cancer affecting women worldwide. The oncogenicity of HPV is mainly attributable to the E6 and E7 oncoproteins. HPV-52 is the seventh most common HPV type globally, but it has a remarkably high prevalence in East Asia. In previous studies it has been speculated that the oncogenicity might vary among different HPV-52 variants. In the present study, we compared the oncogenicity of E6 derived from the HPV-52 prototype and three commonly found variants, V1 (K93R), V2 (E14D/V92L) and V3 (K93R/N122K), through molecular and phenotypic approaches. We demonstrated that cells containing V1 achieved higher colony formation and showed greater cell migration ability when compared to other variants, but no difference in cell immortalization ability was observed. At the molecular level, the three variants formed complexes with E6-associated protein (E6AP) and p53 as efficiently as the prototype. They degraded p53 and PSD95/Dlg/ZO-1(PDZ) proteins, including MAGI-1c and Dlg, to a similar extent. They also exhibited a similar subcellular localization, and shared a half-life of approximately 45 min. Our findings provide a clearer picture of HPV-52 E6 variant oncogenicity, which is important for further studies aiming to understand the unusually high prevalence of HPV-52 among cervical cancers in East Asia.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): E6 , Eastern Asia , human papillomavirus , human papillomavirus type 52 (HPV-52) , oncogenicity and variant
© 2019 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001222
2019-01-24
2025-05-12
Loading full text...

Full text loading...

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359E386 [View Article][PubMed]
     [Google Scholar]
  2. Zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989; 49:4677–4681[PubMed]
     [Google Scholar]
  3. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796–802[PubMed]
     [Google Scholar]
  4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90:1–636[PubMed]
     [Google Scholar]
  5. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano S, Mena M et al. Human Papillomavirus and Related Diseases in the World: Summary Report 27July 2017
     [Google Scholar]
  6. Chan PK, Ho WC, Chan MC, Wong MC, Yeung AC et al. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS One 2014; 9:e107573 [View Article][PubMed]
     [Google Scholar]
  7. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934–937 [View Article][PubMed]
     [Google Scholar]
  8. Hu T, Ferril S, Snider A, Barbosa M. In-vivo analysis of hpv e7 protein association with prb, p107 and p130. Int J Oncol 1995; 6:167–174 [View Article][PubMed]
     [Google Scholar]
  9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129–1136 [View Article][PubMed]
     [Google Scholar]
  10. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10:4129–4135 [View Article][PubMed]
     [Google Scholar]
  11. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 1997; 94:11612–11616 [View Article][PubMed]
     [Google Scholar]
  12. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C et al. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 2002; 21:5088–5096 [View Article][PubMed]
     [Google Scholar]
  13. Niccoli S, Abraham S, Richard C, Zehbe I. The Asian-American E6 variant protein of human papillomavirus 16 alone is sufficient to promote immortalization, transformation, and migration of primary human foreskin keratinocytes. J Virol 2012; 86:12384–12396 [View Article][PubMed]
     [Google Scholar]
  14. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17–27 [View Article][PubMed]
     [Google Scholar]
  15. Aho J, Hankins C, Tremblay C, Lang F, Forest P et al. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J Infect Dis 2003; 188:1517–1527 [View Article][PubMed]
     [Google Scholar]
  16. Xin CY, Matsumoto K, Yoshikawa H, Yasugi T, Onda T et al. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 2001; 170:19–24 [View Article][PubMed]
     [Google Scholar]
  17. Ding T, Wang X, Ye F, Cheng X, Ma D et al. Distribution of human papillomavirus 58 and 52 E6/E7 variants in cervical neoplasia in Chinese women. Gynecol Oncol 2010; 119:436–443 [View Article][PubMed]
     [Google Scholar]
  18. Ishizaki A, Matsushita K, Hoang HT, Agdamag DM, Nguyen CH et al. E6 and E7 variants of human papillomavirus-16 and -52 in Japan, the Philippines, and Vietnam. J Med Virol 2013; 85:1069–1076 [View Article][PubMed]
     [Google Scholar]
  19. Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM et al. Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages. J Infect Dis 2014; 210:1600–1604 [View Article][PubMed]
     [Google Scholar]
  20. Valle GF, Banks L. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 1995; 76:1239–1245 [View Article][PubMed]
     [Google Scholar]
  21. Todorovic B, Massimi P, Hung K, Shaw GS, Banks L et al. Systematic analysis of the amino acid residues of human papillomavirus type 16 E7 conserved region 3 involved in dimerization and transformation. J Virol 2011; 85:10048–10057 [View Article][PubMed]
     [Google Scholar]
  22. Nguyen M, Song S, Liem A, Androphy E, Liu Y et al. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol 2002; 76:13039–13048 [View Article][PubMed]
     [Google Scholar]
  23. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD, Androphy EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 1998; 273:13537–13544 [View Article][PubMed]
     [Google Scholar]
  24. Gardiol D, Galizzi S, Banks L. Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation. J Gen Virol 2002; 83:283–289 [View Article][PubMed]
     [Google Scholar]
  25. Kranjec C, Massimi P, Banks L. Restoration of MAGI-1 expression in human papillomavirus-positive tumor cells induces cell growth arrest and apoptosis. J Virol 2014; 88:7155–7169 [View Article][PubMed]
     [Google Scholar]
  26. Thomas M, Glaunsinger B, Pim D, Javier R, Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001; 20:5431–5439 [View Article][PubMed]
     [Google Scholar]
  27. Togtema M, Jackson R, Richard C, Niccoli S, Zehbe I. The human papillomavirus 16 European-T350G E6 variant can immortalize but not transform keratinocytes in the absence of E7. Virology 2015; 485:274–282 [View Article]
     [Google Scholar]
  28. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998; 58:829–833[PubMed]
     [Google Scholar]
  29. Yamada T, Manos MM, Peto J, Greer CE, Munoz N et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71:2463–2472[PubMed]
     [Google Scholar]
  30. Ridley AJ. Rho GTPase signalling in cell migration. Curr Opin Cell Biol 2015; 36:103–112 [View Article][PubMed]
     [Google Scholar]
  31. Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 2013; 105:393–404 [View Article][PubMed]
     [Google Scholar]
  32. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009; 26:273–287 [View Article]
     [Google Scholar]
  33. Hu D, Zhou J, Wang F, Shi H, Li Y et al. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo. Arch Gynecol Obstet 2015; 292:1345–1354 [View Article][PubMed]
     [Google Scholar]
  34. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009; 384:324–334 [View Article][PubMed]
     [Google Scholar]
  35. Lagrange M, Charbonnier S, Orfanoudakis G, Robinson P, Zanier K et al. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J Gen Virol 2005; 86:1001–1007 [View Article][PubMed]
     [Google Scholar]
  36. Mesplède T, Gagnon D, Bergeron-Labrecque F, Azar I, Sénéchal H et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 2012; 86:94–107 [View Article][PubMed]
     [Google Scholar]
  37. Thomas M, Glaunsinger B, Pim D, Javier R, Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001; 20:5431–5439 [View Article][PubMed]
     [Google Scholar]
  38. Tao M, Kruhlak M, Xia S, Androphy E, Zheng ZM. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells. J Virol 2003; 77:13232–13247 [View Article][PubMed]
     [Google Scholar]
  39. Guccione E, Massimi P, Bernat A, Banks L. Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology 2002; 293:20–25 [View Article][PubMed]
     [Google Scholar]
  40. Vaeteewoottacharn K, Chamutpong S, Ponglikitmongkol M, Angeletti PC. Differential localization of HPV16 E6 splice products with E6-associated protein. Virol J 2005; 2:50 [View Article][PubMed]
     [Google Scholar]
  41. Grossman SR, Mora R, Laimins LA, Localization I. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol 1989; 63:366–374
     [Google Scholar]
  42. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 1987; 6:989–992 [View Article][PubMed]
     [Google Scholar]
  43. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8:3905–3910 [View Article][PubMed]
     [Google Scholar]
  44. Griffin LM, Cicchini L, Xu T, Pyeon D. Human keratinocyte cultures in the investigation of early steps of human papillomavirus infection. Methods in Molecular Biology Clifton, NJ: pp. 219–238
     [Google Scholar]
  45. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998; 17:2943–2954 [View Article][PubMed]
     [Google Scholar]
  46. Hsu CH, Peng KL, Jhang HC, Lin CH, Wu SY et al. The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription. Oncogene 2012; 31:2335–2349 [View Article][PubMed]
     [Google Scholar]
  47. Tomaić V, Gardiol D, Massimi P, Ozbun M, Myers M et al. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene 2009; 28:1–8 [View Article]
     [Google Scholar]
  48. Pim D, Tomaic V, Banks L. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein. J Virol 2009; 83:9863–9874 [View Article][PubMed]
     [Google Scholar]
  49. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7:961–963 [View Article][PubMed]
     [Google Scholar]
  50. Thomas M, Kalita A, Labrecque S, Pim D, Banks L et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092–1100 [View Article][PubMed]
     [Google Scholar]
  51. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000; 19:5270–5280 [View Article][PubMed]
     [Google Scholar]
  52. Massimi P, Banks L. Transformation assays for HPV oncoproteins. Human Papillomaviruses NJ: Humana Press; pp. 381–396
     [Google Scholar]
  53. Matlashewski G, Schneider J, Banks L, Jones N, Murray A et al. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J 1987; 6:1741–1746 [View Article][PubMed]
     [Google Scholar]
  54. Storey A, Banks L. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 1993; 8:919–924[PubMed]
     [Google Scholar]
  55. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991; 65:473–478[PubMed]
     [Google Scholar]
  56. Tomaic V, Pim D, Thomas M, Massimi P, Myers MP et al. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol 2011; 85:3120–3127 [View Article][PubMed]
     [Google Scholar]
  57. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70:245–252 [View Article][PubMed]
     [Google Scholar]
  58. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229–234 [View Article][PubMed]
     [Google Scholar]
  59. Zhou P. Determining protein half-lives. Signal Transduction Protocols NJ: Humana Press; pp. 67–78
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001222
Loading
Oncogenicitiy Comparison of Human Papillomavirus Type 52 E6 Variants
J. Gen. Virol. 100, 484 (2019); https://doi.org/10.1099/jgv.0.001222
/content/journal/jgv/10.1099/jgv.0.001222
/content/journal/jgv/10.1099/jgv.0.001222
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error